AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15847251 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily for four weeks, increased to 80 mg if DBP >= 85 mmHg after four or eight weeks.
Number of subjects: 82
Study 15847251 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan treatment
Number of subjects: 82
Study 12774056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow donation
Number of subjects: 2
Study 12774056 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood stem cells (PBSCs) donation
Number of subjects: 2
Study 12774056 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF stimulated stem cell donation
Number of subjects: 2
Study 10420392 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline chitosan (MCCh; 3 capsules, each 400 mg b.i.d.)
Number of subjects: 51
Study 10420392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10420392 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline chitosan (MCCh)
Number of subjects: 51
Study 8024918 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional ilioinguinal and iliohypogastric nerve block and wound infiltration with 0.5% bupivacaine
Number of subjects: 40
Study 8024918 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 2702229 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler use
Number of subjects: 238
Study 1247149 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm reversed jejunal segment
Number of subjects: 11
Study 1247149 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal placed at the gastric outlet
Number of subjects: 11
Study 1247149 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal placed just below the ligament of Treitz
Number of subjects: 11
Study 30688377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc
Number of subjects: 40
Study 30688377 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next (PTN)
Number of subjects: 40
Study 30688377 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG)
Number of subjects: 40
Study 30688377 — intervention group
Group type: COMPARATOR
Intervention: ProDesign Logic (PDL)
Number of subjects: 40
Study 27646508 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based incentive
Number of subjects: 191
Study 27646508 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional direct payment incentive
Number of subjects: 191
Study 27646508 — intervention group
Group type: COMPARATOR
Intervention: Control (daily feedback without any incentive)
Number of subjects: 191
Study 26098793 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C-CT)
Number of subjects: 241
Study 26098793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 241
Study 26098793 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo (PBO)
Number of subjects: 241
Study 23786536 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (100 mg/day) for 1 month
Number of subjects: 22
Study 21930542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous needle (ION) placement
Number of subjects: 40
Study 21930542 — intervention group
Group type: COMPARATOR
Intervention: Umbilical venous catheter (UVC) placement
Number of subjects: 40
Study 18359910 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound
Number of subjects: 0
Study 18359910 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic ultrasound exposure during pregnancy
Number of subjects: 0
Study 16374892 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 38
Study 14636905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day titrated to 80 mg/day
Number of subjects: 623
Study 14636905 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day titrated to 80 mg/day
Number of subjects: 623
Study 14636905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 and 80 mg
Number of subjects: 623
Study 14636905 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 623
Study 14636905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Rosuvastatin and Atorvastatin)
Number of subjects: 623
Study 11000355 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed carbon dioxide gas (37 degrees C)
Number of subjects: 20
Study 11000355 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature carbon dioxide gas (21 degrees C)
Number of subjects: 20
Study 11000355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Warmed and Cold)
Number of subjects: 20
Study 8626819 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium intake (60.4 ± 6.5 mmol/day [2414 ± 260 mg/day]; n = 13)
Number of subjects: 28
Study 8626819 — intervention group
Group type: COMPARATOR
Intervention: Usual calcium intake (20.4 ± 7.2 mmol/day [815 ± 289 mg/day]; n = 15)
Number of subjects: 28
Study 8626819 — intervention group
Group type: COMPARATOR
Intervention: Young group (12 normal young adult women, age 30.1 ± 4.4 years)
Number of subjects: 28
Study 1589234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (3 x 100 U/day)
Number of subjects: 66
Study 1589234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 sprays)
Number of subjects: 66
Study 2424102 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus weekly injection of bleomycin 15 mg and mitomycin C 4 mg
Number of subjects: 300
Study 2424102 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 300
Study 29641281 — intervention group
Group type: EXPERIMENTAL
Intervention: TissueGene‐C (TG‐C)
Number of subjects: 163
Study 29641281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 27263311 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal position (Group I)
Number of subjects: 180
Study 27263311 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position 5 degrees (Group II)
Number of subjects: 180
Study 27263311 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position 10 degrees (Group III)
Number of subjects: 180
Study 27263311 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 180
Study 24113564 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect intervention (LEAF)
Number of subjects: 24
Study 24113564 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 24
Study 22765917 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (20mg/kg) administered at 0h, 3h, or 24h after SE, followed by once daily treatment for 20 days
Number of subjects: 0
Study 22765917 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (20mg/kg) administered after SE
Number of subjects: 0
Study 22765917 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (20mg/kg) administered at 3h or 24h after SE
Number of subjects: 0
Study 20705277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognate words
Number of subjects: 0
Study 20705277 — intervention group
Group type: COMPARATOR
Intervention: Control matched words
Number of subjects: 0
Study 18822175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve root decompression according to Gill (unilateral or bilateral)
Number of subjects: 0
Study 18822175 — intervention group
Group type: COMPARATOR
Intervention: Instrumented spondylodesis (pedicle screw fixation with interbody fusion)
Number of subjects: 0
Study 15828938 — intervention group
Group type: EXPERIMENTAL
Intervention: LyphoDerm + standard care (hydrocolloid dressing and compression therapy)
Number of subjects: 194
Study 15828938 — intervention group
Group type: COMPARATOR
Intervention: Standard care + vehicle
Number of subjects: 194
Study 15828938 — intervention group
Group type: EXPERIMENTAL
Intervention: LyphoDerm + standard care (hydrocolloid dressing and compression therapy) in patients with enlarging ulcers
Number of subjects: 194
Study 15828938 — intervention group
Group type: COMPARATOR
Intervention: Standard care + vehicle in patients with enlarging ulcers
Number of subjects: 194
Study 12424538 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 12 (Group 1)
Number of subjects: 55
Study 12424538 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 17 (Group 2)
Number of subjects: 55
Study 12424538 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no G‐CSF)
Number of subjects: 55
Study 10638406 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m-tetrofosmin
Number of subjects: 101
Study 10638406 — intervention group
Group type: COMPARATOR
Intervention: Technetium-99m-MIBI
Number of subjects: 101
Study 7549803 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet plus soy foods
Number of subjects: 19
Study 7549803 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet plus carotenoid-rich vegetables
Number of subjects: 19
Study 7549803 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet plus cruciferous vegetables
Number of subjects: 19
Study 7549803 — intervention group
Group type: COMPARATOR
Intervention: Control diet alone
Number of subjects: 19
Study 1659172 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, high-fiber diet (HCHF)
Number of subjects: 10
Study 1659172 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate, low-fiber diet (LCLF)
Number of subjects: 10
Study 7048863 — intervention group
Group type: EXPERIMENTAL
Intervention: AMCA (tranexamic acid)
Number of subjects: 105
Study 7048863 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 30554611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise-heat exposures (IHE) every fifth day for 25 days
Number of subjects: 16
Study 30554611 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) that exercised in a temperate environment (24°C, 21%RH)
Number of subjects: 16
Study 30027496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 66
Study 30027496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 27552463 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PITT technique
Number of subjects: 8
Study 27552463 — intervention group
Group type: COMPARATOR
Intervention: Interference screw technique
Number of subjects: 8
Study 24796970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 30, 50, or 70 mg/day
Number of subjects: 30
Study 24796970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 30
Study 21476945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed home telehealth intervention
Number of subjects: 0
Study 21476945 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity remote monitoring
Number of subjects: 0
Study 21476945 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 19848574 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart applied with the FlexPen (IAFP)
Number of subjects: 12
Study 19848574 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary human insulin applied with the Exubera device (HIEX)
Number of subjects: 12
Study 19848574 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexPen
Number of subjects: 12
Study 19848574 — intervention group
Group type: COMPARATOR
Intervention: Exubera
Number of subjects: 12
Study 17567421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine vesicoamniotic shunting for fetal bladder outflow obstruction
Number of subjects: 0
Study 17567421 — intervention group
Group type: COMPARATOR
Intervention: Conservative, noninterventional care (expectant management)
Number of subjects: 0
Study 15502026 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 87
Study 15502026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg)
Number of subjects: 87
Study 15502026 — intervention group
Group type: COMPARATOR
Intervention: Atracurium and Cisatracurium
Number of subjects: 87
Study 11207172 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine
Number of subjects: 195
Study 11207172 — intervention group
Group type: COMPARATOR
Intervention: Deferred zidovudine (matching placebo)
Number of subjects: 195
Study 11207172 — intervention group
Group type: EXPERIMENTAL
Intervention: All children regardless of original allocation
Number of subjects: 195
Study 9576371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% amino acid dialysis solution (Nutrineal)
Number of subjects: 20
Study 9576371 — intervention group
Group type: COMPARATOR
Intervention: 1.5% dextrose Dianeal
Number of subjects: 20
Study 7932287 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 100
Study 7932287 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 100
Study 2979240 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 2979240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31826682 — intervention group
Group type: COMPARATOR
Intervention: csDMARDs
Number of subjects: 306
Study 29972210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=20) consuming a daily 200mL liquid juice containing 3000mg omega-3 PUFAs, 10μg vitamin D3, 150mg resveratrol, and 8g whey protein isolate
Number of subjects: 37
Study 29972210 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=17) consuming a daily 200mL juice only
Number of subjects: 37
Study 27413129 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change intervention
Number of subjects: 248
Study 27413129 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 248
Study 25601244 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based simulation course training
Number of subjects: 116
Study 25601244 — intervention group
Group type: COMPARATOR
Intervention: Traditional course
Number of subjects: 116
Study 23876590 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.1 mg) twice daily
Number of subjects: 46
Study 23876590 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 46
Study 19788433 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulin 150U
Number of subjects: 16
Study 19788433 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulin 300U
Number of subjects: 16
Study 19788433 — intervention group
Group type: COMPARATOR
Intervention: Actrapid 12U
Number of subjects: 16
Study 19788433 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulin (150U twice daily during repeat dosing)
Number of subjects: 16
Study 19025390 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing procedure real-time on the video monitor
Number of subjects: 100
Study 19025390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no viewing of the screen)
Number of subjects: 100
Study 16487438 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyroid group (L‐thyroxine plus placebo)
Number of subjects: 24
Study 16487438 — intervention group
Group type: COMPARATOR
Intervention: Low‐TSH group (L‐thyroxine)
Number of subjects: 24
Study 12964065 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 26
Study 12964065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12964065 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 26
Study 11083213 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 30
Study 11083213 — intervention group
Group type: COMPARATOR
Intervention: Open classic technique
Number of subjects: 30
Study 9200848 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,2,4‐TMB alone
Number of subjects: 9
Study 9200848 — intervention group
Group type: COMPARATOR
Intervention: White spirit
Number of subjects: 9
Study 1487561 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg
Number of subjects: 18
Study 1487561 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg
Number of subjects: 18
Study 1487561 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 18
Study 1487561 — intervention group
Group type: EXPERIMENTAL
Intervention: O-desmethylvenlafaxine (active metabolite)
Number of subjects: 18
Study 1487561 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite parameter (AUC + activity factor.AUCm)
Number of subjects: 18
Study 1487561 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine and O-desmethylvenlafaxine
Number of subjects: 18
Study 3161013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (mean dose 71 mg/d)
Number of subjects: 20
Study 3161013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31326345 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) capsules (75 capsules over 3 days, each containing approximately 0.38 g of minimally processed donor stool)
Number of subjects: 48
Study 31326345 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (75 capsules over 3 days)
Number of subjects: 48
Study 31326345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during FMT
Number of subjects: 48
Study 29953740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet and liraglutide treatment (HFL)
Number of subjects: 40
Study 29953740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chow diet (HFC)
Number of subjects: 40
Study 29953740 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined liraglutide and dietary intervention (HFCL)
Number of subjects: 40
Study 29953740 — intervention group
Group type: COMPARATOR
Intervention: Continued high-fat diet (HF)
Number of subjects: 40
Study 25637044 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBNP
Number of subjects: 116
Study 25637044 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NIT)
Number of subjects: 116
Study 23760610 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (TC)
Number of subjects: 625
Study 23760610 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling (FC)
Number of subjects: 625
Study 23760610 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 625
Study 22861074 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 127
Study 22861074 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 127
Study 22861074 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 127
Study 19828592 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time wear (30 patients)
Number of subjects: 62
Study 19828592 — intervention group
Group type: COMPARATOR
Intervention: Part-time wear (32 patients)
Number of subjects: 62
Study 17888806 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy plus usual care (PST-UC)
Number of subjects: 254
Study 17888806 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation plus usual care (PC-UC)
Number of subjects: 254
Study 17888806 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 254
Study 15050906 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 38
Study 15050906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11576036 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 71
Study 11576036 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 71
Study 9819368 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (YHO)
Number of subjects: 16
Study 9819368 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (CLO)
Number of subjects: 16
Study 8619339 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (150 mg/day)
Number of subjects: 77
Study 8619339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 2711992 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 or 360 mg/day)
Number of subjects: 34
Study 2711992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg oral carbuterol
Number of subjects: 26
Study 18957 — intervention group
Group type: COMPARATOR
Intervention: 35 mg ephedrine sulfate
Number of subjects: 26
Study 31482633 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Zanthoxylum bungeanum maxim extract
Number of subjects: 20
Study 31482633 — intervention group
Group type: COMPARATOR
Intervention: Vehicle formulation
Number of subjects: 20
Study 28095938 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient communication group (received the patient‐to‐patient communication model)
Number of subjects: 65
Study 28095938 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician communication group
Number of subjects: 65
Study 28095938 — intervention group
Group type: COMPARATOR
Intervention: Routine communication group
Number of subjects: 65
Study 25816713 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (25-50 mg)
Number of subjects: 19
Study 25816713 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (2.5-5 mg)
Number of subjects: 19
Study 25816713 — intervention group
Group type: COMPARATOR
Intervention: both drugs
Number of subjects: 19
Study 23283255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.25 mg/kg
Number of subjects: 91
Study 23283255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg/kg
Number of subjects: 91
Study 23283255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 91
Study 20723985 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPP-A levels ≥ 11.33 mIu/L
Number of subjects: 129
Study 20723985 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPP-A levels < 11.33 mIu/L
Number of subjects: 129
Study 20723985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein levels
Number of subjects: 129
Study 20077989 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Nursing Rehabilitation Program (CNRP)
Number of subjects: 24